Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2015

Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2015

Code: GMDHC7417IDB | Published: Dec-2015 | Pages: 1178 | Global Markets Direct
Price :

* Required Fields



Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2015


Global Markets Directs, Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2015, provides an overview of the Glioblastoma Multiforme (GBM)s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

AbbVie Inc.
Actelion Ltd
Actinium Pharmaceuticals, Inc.
Actinogen Limited
Activartis Biotech GmbH
Aduro BioTech, Inc.
Advanced Accelerator Applications SA
Advanced Cancer Therapeutics
Advenchen Laboratories, LLC
Agenus, Inc.
Amal Therapeutics SA
Ambrx, Inc.
Amgen Inc.
Ampio Pharmaceuticals, Inc.
AngioChem Inc.
APIM Therapeutics AS
Apogenix GmbH
Argon Pharma S.L.
Ariad Pharmaceuticals, Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Axelar AB
BeiGene(Beijing) Co.,Ltd
Bexion Pharmaceuticals, LLC.
Bioasis Technologies Inc.
BioCancell Ltd
Biomar Microbial Technologies
Bioncotech Therapeutics S.L.
Biovista Inc.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Caladrius Biosciences, Inc.
CalAsia Pharmaceuticals, Inc.
Cavion LLC
Celgene Corporation
Celldex Therapeutics, Inc.
Cellectis S.A.
Celltrion, Inc.
Celsion Corporation
Champions Oncology, Inc.
ChemoCentryx, Inc.
CLL Pharma
CTI BioPharma Corp.
CureFAKtor Pharmaceuticals, LLC
CytomX Therapeutics, Inc.
CytoVac A/S
CytRx Corporation
Deciphera Pharmaceuticals, LLC
Delenex Therapeutics AG
Diffusion Pharmaceuticals LLC
DiscoveryBiomed, Inc.
Dr. Reddys Laboratories Limited
e-Therapeutics Plc
Ecrins Therapeutics SAS
EirGenix Inc.
Eisai Co., Ltd.
Eli Lilly and Company
EnGeneIC Ltd
EntreChem, S.L.
Epirus Biopharmaceuticals, Inc.
ERC Belgium SA
Evotec AG
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
FirstString Research, Inc.
Five Prime Therapeutics, Inc.
Galileo Research s.r.l.
Genentech, Inc.
Genor BioPharma Co., Ltd.
GenSpera, Inc.
Genzyme Corporation
GlaxoSmithKline Plc
GW Pharmaceuticals Plc
HEC Pharm Co., Ltd.
Hospira, Inc.
immatics biotechnologies GmbH
ImmunoCellular Therapeutics, Ltd.
Immunocore Limited
Immunomic Therapeutics, Inc.
Immunovaccine, Inc.
Infinity Pharmaceuticals, Inc.
INSYS Therapeutics, Inc.
InteRNA Technologies B.V.
Intica Biomedical, Inc.
Jiangsu Kanion Pharmaceutical Co., Ltd.
Johnson & Johnson
Kadmon Corporation, LLC
Kalgene Pharmaceuticals Inc.
KaloBios Pharmaceuticals, Inc.
Karyopharm Therapeutics, Inc.
Kite Pharma, Inc.
Komipharm International Co., Ltd.
Lentigen Technology, Inc.
Les Laboratoires Servier SAS
LinXis B.V.
Lixte Biotechnology Holdings, Inc.
Loxo Oncology, Inc.
Mabion SA
Medicenna Therapeutics, Inc
MedImmune, LLC
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
Mycenax Biotech Inc.
Nascent Biotech, Inc.
Nemucore Medical Innovations, Inc.
Nerviano Medical Sciences S.r.l.
Neuralstem, Inc.
NewLink Genetics Corporation
Nexgenix Pharmaceuticals, LLC
Northwest Biotherapeutics, Inc.
Novartis AG
Novogen Limited
Noxxon Pharma AG
Omniox, Inc.
Oncobiologics, Inc.
Oncodesign SA
Oncolytics Biotech Inc.
Onconova Therapeutics, Inc.
Ono Pharmaceutical Co., Ltd.
Orphagen Pharmaceuticals, Inc.
Oryx GmbH & Co. KG
Panacea Biotec Limited
Panacela Labs, Inc.
Peloton Therapeutics, Inc.
Peregrine Pharmaceuticals, Inc.
Pfizer Inc.
PharmAbcine, Inc.
PharmaCyte Biotech, Inc.
Plexxikon Inc.
Prana Biotechnology Limited
Progenics Pharmaceuticals, Inc.
Regulus Therapeutics Inc.
RestorGenex Corporation
Rexahn Pharmaceuticals, Inc.
Rigontec GmbH
Sagetis Biotech, S.L.
Selvita SA
Siena Biotech S.p.A.
Sigma-Tau S.p.A.
Sirnaomics, Inc.
Sorrento Therapeutics, Inc.
Spectrum Pharmaceuticals, Inc.
STELIS Biopharma Pvt. Ltd.
Stemline Therapeutics, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Sun Pharmaceutical Industries Limited
Susavion Biosciences, Inc.
Terpenoid Therapeutics, Inc.
Therapeia GmbH & Co. KG
Theravectys SA
Threshold Pharmaceuticals, Inc.
Tocagen Inc.
TRACON Pharmaceuticals, Inc.
TVAX Biomedical, Inc.
Upsher-Smith Laboratories, Inc.
Vascular Biogenics Ltd.
VBI Vaccines Inc.
Vertex Pharmaceuticals Incorporated
ViraTherapeutics GmbH
Virttu Biologics Limited
ZIOPHARM Oncology, Inc.

Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]

2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal

3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at


There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
Global Markets Direct

Our Clients